Tags : Axsome

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More

Axsome In-Licenses Pfizer’s Reboxetine and Esreboxetine in the US

Shots: Pfizer to receive Axsome’s common shares of ~$8M, $3M in cash as upfront, ~$323M regulatory & commercial milestones and royalties in sales of the therapies and has right of first negotiation on any potential strategic transactions involving AXS-12 and AXS-14 Axsome to receive an exclusive license to Pfizer’s clinical, nonclinical data and intellectual property […]Read More